NDAOPHTHALMICINSERT
Approved
Jun 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
LACRISERT (hydroxypropyl cellulose) by Bausch + Lomb is clinical pharmacology pharmacodynamics lacrisert acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Approved for moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. First approved in 1981.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LACRISERT is a hydroxypropyl cellulose ophthalmic insert administered once daily in the conjunctival sac for moderate to severe dry eye syndrome and keratoconjunctivitis sicca. It stabilizes and thickens the precorneal tear film, prolonging tear film breakup time and lubricating/protecting the eye. The insert dissolves gradually over 14-24 hours, providing sustained symptomatic relief superior to artificial tears.
$0.017BPart D
LOE ApproachingDeclining
Modest market presence with declining utilization signals a mature product approaching loss of exclusivity; brand team is likely in maintenance/transition mode rather than growth expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics LACRISERT acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. LACRISERT also acts to lubricate and protect the eye. LACRISERT usually reduces the signs and…
Worked on LACRISERT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.